A patient died in a trial for a new cancer treatment and shares of the company behind it are collapsing
Phil Noble/Reuters
The company has been developing a treatment called JCAR015 that uses genetically engineered cells to go after a form of adult leukemia.
According to a release from the company, the phase two trial was put on hold after two patients suffered cerebral edema - a dangerous build up of fluid in the brain - this week. One patient has died and another is not expected to recover according to the release
The treatment was previously placed on hold in July after the death of two patients, but was eventually resumed.
"Juno has notified the Food & Drug Administration of the voluntary hold and is working with the agency and the Data and Safety Monitoring Board to determine next steps," Juno said in the press release. "The company is assessing data from the cases and the trial and is evaluating its options regarding the JCAR015 program."
The stock was halted in pre-market trading early Wednesday, and fell over 45% when trade resumed. Since that point, shares have recovered and the stock is down around 30% to $20.50 a share as of 8:40 a.m. ET.
Yahoo Finance
- A couple accidentally shipped their cat in an Amazon return package. It arrived safely 6 days later, hundreds of miles away.
- A centenarian who starts her day with gentle exercise and loves walks shares 5 longevity tips, including staying single
- 2 states where home prices are falling because there are too many houses and not enough buyers
- 7 Nutritious and flavourful tiffin ideas to pack for school
- India's e-commerce market set to skyrocket as the country's digital economy surges to USD 1 Trillion by 2030
- Top 5 places to visit near Rishikesh
- Indian economy remains in bright spot: Ministry of Finance
- A surprise visit: Tesla CEO Elon Musk heads to China after deferring India visit